Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2024-05-14 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于完成监事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the completion of the supervisory board (监事会) re-election at Zhejiang Tailin Biotechnology Co., Ltd. It details the election of new supervisory board members, their qualifications, and changes in personnel. There is no financial data, no mention of annual or interim reports, no audit information, and no regulatory certifications. The content focuses on changes in the company's supervisory board members, which falls under management or board information disclosures. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2024-05-14 Chinese
关于聘任高级管理人员、证券事务代表及内审部负责人的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the appointment of senior management personnel, securities affairs representatives, and the head of the internal audit department. It details the names, qualifications, and backgrounds of the appointed individuals, along with compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on management changes and appointments, which fits the category of Board/Management Information (MANG). The document length is about 5,077 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or other types of filings.
2024-05-14 Chinese
第四届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the first meeting of the fourth board of directors of Zhejiang Tailin Biotechnology Co., Ltd. It details the election of the board chairman, appointment of board committees, and hiring of senior management personnel. The content focuses on board and management changes, including appointments and committee memberships, with voting results. There is no financial data, earnings information, or report publication mentioned. The document is not a full report but an official announcement of board and management decisions. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2335 characters, consistent with an announcement rather than a full report.
2024-05-14 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司2023年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2023年度持续督导跟踪报告" (2023 Annual Continuous Supervision Follow-up Report) issued by a sponsoring institution (长城证券股份有限公司) regarding 浙江泰林生物技术股份有限公司. It details the sponsor's supervision activities, including information disclosure review, governance supervision, fundraising supervision, and other compliance and operational oversight activities. The document includes tables summarizing work done, issues found, and commitments fulfilled by the company and shareholders. It is not a full annual report or financial statement but a regulatory supervision follow-up report related to the sponsor's duties. The document length is 2667 characters, relatively short and focused on supervision and compliance tracking rather than financial results or management discussion. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance and supervision report that does not fit other specific categories like Annual Report, Interim Report, or Audit Report. Therefore, the classification is RNS with high confidence.
2024-05-10 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司2023年度持续督导定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导定期现场检查报告" which translates to "2023 Annual Continuous Supervision On-site Inspection Report" by the sponsor Great Wall Securities Co., Ltd. for Zhejiang Tailin Biotechnology Co., Ltd. It contains detailed findings from on-site inspections related to corporate governance, internal controls, information disclosure, use of raised funds, and performance issues for the year 2023. It includes audit-like assessments but is not a standalone audit report or full annual report. The document is about regulatory supervision and compliance checks rather than financial statements or earnings announcements. It is a formal inspection report by the sponsor, which fits the category of Audit Report / Information (AR) as it relates to audit and regulatory compliance findings without being a full annual report or earnings release. The document length is 4204 characters, which is substantive and contains detailed inspection content, not just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2023
2024-05-10 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding abnormal stock price fluctuations over three consecutive trading days, with explanations and risk warnings. It references stock codes, dates, and regulatory rules from the Shenzhen Stock Exchange. The content focuses on stock price volatility, company disclosures, and investor risk reminders. There is no financial data, no detailed financial report, no management discussion, no voting results, no executive changes, no merger or acquisition information, and no audit or earnings report. The document is a regulatory announcement about stock trading behavior and company disclosures related to that, fitting the category of a Regulatory Filing (RNS). The document length is short (1112 characters), and it is not a report publication announcement or certification letter but a regulatory disclosure about stock price abnormality.
2024-05-09 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.